Therapeutic plasma exchange (mTPE) removes and replaces a patient’s blood plasma and can treat several autoimmune diseases. The antibodies in autoimmune diseases are known for attacking specific parts of the body and cause a spectrum of symptoms, depending on the target.
The process starts with the removal of plasma, which is then pumped through a large-pore membrane of the plasma filter. The growing prevalence of such autoimmune diseases is subsequently boosting the market growth, which is further grabbing the attention of several emerging players in the therapeutic plasma exchange (mTPE) device market. For instance, recently, Baxter—a pioneer and a single leader in the industry—introduced ‘PRISMAFLEX System,’ a flexible, filter-based solution that meets the demand of multiple therapies. The device is backed with a number of features including, accurate fluid management, streamlined alarm management, patented deaeration chamber, and innovative sterile solution. It is specially designed for providing healthcare professionals with more efficacy in the delivery of continuous renal replacement therapy (CRRT) and therapeutic plasma exchange (TPE) therapies. Apart from this, supportive government regulations for reimbursement policies regarding healthcare and rising consolidation for healthcare amenities are adding fuel to the market growth.
The rising prevalence of chronic diseases and intensive research and clinical trials are the factors contributing to the market growth. The players in the mTPE device market are arduously working to provide user-friendly devices with consolidated safety and low maintenance cost to patients across the globe. For the record, the mTPE device decreases the maintenance cost by choosing a membrane that complies with the individual patient requirements, which is further boosting the market growth.
In the mTPE device market, Baxter manufactures highly specialized filtering blood purification therapies and ensures utmost patient safety. For nurses and clinicians, the ‘PRISMAFLEX System’ helps to save time by providing automatic adjustments allied with immediate visual feedback of the system’s status.
The key segments of the mTPE device market the therapeutic application, therapeutic types, and end-user.
By therapeutic application, the mTPE device market is segmented into plasma or red cell exchange, cell depletion, granulocyte collection, and stem cell collection. The stem cell collection segment is dominating the market and will continue the same during the forecast period.
On the basis of therapeutic type, the mTPE device market is segmented into hemophilia, bone marrow, platelet transfusion, and renal dialysis. The platelet transfusion is projected to capture a major market share with the highest CAGR.
By end-user, the mTPE device market is segmented into hospitals, research laboratories, blood banks, and blood transfusion laboratories. The hospital segment is leading the mTPE device market on account of increasing patient pool, rising prevalence of several diseases, and shifting preference towards technologically advanced medical treatments. The research laboratories segment is projected to increase at a significant pace during the forecast period.
North America is holding one of the largest shares in the global mTPE device market. The region is backed by the presence of leading industry players, increasing patient pool, and rising population. Moreover, rapid expansion and a surge in the number of research and academic institutions in the region are boosting the market growth. In addition, the Institutional Ethical Committee and Medical Research Councils are two such prominent research institutes in the market. Other factors driving the market growth include the rising prevalence of neurological diseases, increasing clinical response rate for therapeutic plasma exchange for the treatment of Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis, and growing prevalence of multiple sclerosis.
Europe is second in the global mTPE device market and will continue the same during the forecast period. This can be attributed to the well-equipped healthcare infrastructure, advanced medical technologies, and a high population base. The region is likely to emboss an impressive footprint in the overall mTPE device market in the years to come.
Asia Pacific is the fastest growing mTPE device market on account of raising awareness of diagnosis among the patients, rising expenditure power, government support, rising investments by leading players, and the presence of major players. The key markets gaining high profitability index include Japan, China, Australia, Singapore, and New Zealand. In the region, China is dominating the mTPE device market; whereas, India is expected to witness significant growth during the forecast period.
Furthermore, LAMEA is projected to witness steady growth during the forecast period.
Global mTPE device market has the presence of established players that are acquiring emerging players for expanding their portfolio and increasing their market share. Baxter is one of the major companies functional in the mTPE device market. It offers a wide range of product pipelines with continuous advancements and up-gradations to sustain in the cut-throat competition.
In 2013, Baxter acquired Gambro to expand its therapeutic product portfolio and geographical reach. Apart from this, raising awareness among the patients and physicians concerning the company’s products is further boosting the company's growth.
On 11th February 2019:NantHealth and Baxter International Inc. announced that NantHealth digital Health Solution is now available to connect Baxter’s ‘Prismaflex system’ to a hospital Electronic Medical Record (EMR).Prismaflex is extensively used for treating patients in ICU with acute kidney injury (AKI) and certain life-threatening blood and autoimmune conditions.